Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (441-450 of 713) with videos related to

Pageof 72
Sort By:
Blood|October 5, 2014
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Constantine S Tam, Susan O'Brien, William Plunkett, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2014
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosisElias Jabbour, Hady Ghanem, Xuelin Huang, et al.
Blood|October 7, 2010
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapyFarhad Ravandi, Jorge Cortes, Stefan Faderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Phase I study of bortezomib in refractory or relapsed acute leukemiasJorge Cortes, Deborah Thomas, Charles Koller, et al.
Haematologica|May 2, 2016
Chronic myeloid leukemia: reminiscences and dreamsTariq I Mughal, Jerald P Radich, Michael W Deininger, et al.
Blood|December 2, 2004
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, et al.
Blood|December 9, 2008
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapyElias Jabbour, Hagop M Kantarjian, Dan Jones, et al.
Cancer|August 14, 2002
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphomaBouthaina S Dabaja, Chul S Ha, Deborah A Thomas, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Oncotarget|October 3, 2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Pageof 72

Showing results (441-450 of 713) with videos related to

Sort By:
Pageof 72
Blood|October 5, 2014
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Constantine S Tam, Susan O'Brien, William Plunkett, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2014
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosisElias Jabbour, Hady Ghanem, Xuelin Huang, et al.
Blood|October 7, 2010
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapyFarhad Ravandi, Jorge Cortes, Stefan Faderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Phase I study of bortezomib in refractory or relapsed acute leukemiasJorge Cortes, Deborah Thomas, Charles Koller, et al.
Haematologica|May 2, 2016
Chronic myeloid leukemia: reminiscences and dreamsTariq I Mughal, Jerald P Radich, Michael W Deininger, et al.
Blood|December 2, 2004
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, et al.
Blood|December 9, 2008
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapyElias Jabbour, Hagop M Kantarjian, Dan Jones, et al.
Cancer|August 14, 2002
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphomaBouthaina S Dabaja, Chul S Ha, Deborah A Thomas, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Oncotarget|October 3, 2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Pageof 72